Stocks rallying after wages in December grew at a slower than expected rate. We dig into what it means for the Fed and your money. The FDA expected to decide on Biogen’s second Alzheimer’s treatment, Jefferies’ analyst Michael Yee tells us what makes this drug different than its maligned first drug Aduhelm. Plus, “A Random Walk Down Wall Street” 50 years later. Wall St. legend Burt Malkiel makes his case for passive investing and why investors shouldn’t trust historic returns…especially now.

It’s the countdown to the Fed Minutes and everyone is wondering whether there will be signs of a fracture about what the Fed should do next. We’ll get you set up and run through the latest jobs and inflation numbers. Plus, more DC drama as the GOP struggles to elect a House Speaker. We look at why this could set the stage for two years of tail risk, and the potential fallout for the economy and the markets. And, speaking of markets, if you’re stock picker, you can get some high quality names at bargain prices right now. Our market guest brings four of his favorites…and there’s a twist.